

20th January, 2020

(1) BSE Ltd
Listing Department
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001

(2) National Stock Exchange of India Ltd
Listing Department
Exchange Plaza, 5th floor,
Plot no. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai - 400 051

Scrip Code: 500087

Scrip Code: CIPLA EQ

(3) SOCIETE DE LA BOURSE DE LUXEMBOURG
Societe Anonyme
35A Boulevard Joseph II,
L-1840 Luxembourg

Sub: Closure of USFDA inspection at Patalganga manufacturing facility

Dear Sir / Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that following the inspection by the United States Food and Drug Administration (USFDA) at the Patalganga manufacturing facility of the Company from November 4, 2019 to November 13, 2019, the Company has received the Establishment Inspection Report (EIR), indicating closure of the inspection.

Request you to kindly take note of the above.

Thank you.

Yours faithfully,
For Cipla Limited



Rajendra Chopra
Company Secretary

Prepared by: Gaurav Sainani